Measurement of squalene in human tissues and plasma: validation and application

George C. K. Liu, E. H. Ahrens, Jr., Paul H. Schreibman, and John R. Crouse
Rockefeller University, New York, N.Y. 10021

Abstract A method is described for accurate and reproducible measurement of squalene in plasma, feces, urine, bile, and tissue that depends on isolation by alumina columns, chromatography after mild saponification and on measurement by gas-liquid chromatography. Recoveries from all tissues exceeded 80% and from plasma 96%; losses were accurately corrected by appropriate additions of squalene as an overall recovery standard.

Squalene measurements in more than 20 foodstuffs showed a 5000-fold variation, the richest source being olive oil (7 mg/g); however, the mean intake/person-day in the United States appears to be in the range of 30 mg. Squalene concentrations in more than 25 human tissues also varied widely; the highest levels were in skin (about 475 μg/g dry weight) and adipose tissue (about 275 μg/g), while only moderate amounts were found in sites of active cholesterol synthesis (liver, 75 μg/g; small intestine, 42 μg/g). There was a direct relationship between plasma levels of squalene and triglycerides but not with cholesterol. Plasma squalene levels rose strikingly with increased dietary squalene and varied directly but not consistently with cholesterol synthesis rates. The large amounts excreted in skin surface lipids are presumed to reflect de novo synthesis in the skin, rather than transfer from plasma; only trivial amounts were excreted in feces and urine.

Supplementary key words gas-liquid chromatography • internal standards • stability during storage • diet squalene • hyperglyceridemia

In 1964 Goodman (1) demonstrated the presence of small amounts of metabolically active squalene in human and rat plasma, with most of the labeled squalene transported in the very low density (d <1.019) fraction by intravenous administration of [2,3H]mevalonate. He proposed that the small plasma pool of squalene (about 35 μg/dl) was in rapid equilibrium with a much larger squalene pool in the liver, estimated by Langdon and Bloch (2) to be about 25 μg/g wet weight. Goodman’s paper summarized the literature on the natural occurrence of squalene in various oils, as well as its important place in the biosynthesis of cholesterol.

Since 1964 a number of interesting reports have appeared in regard to squalene metabolism, notably the isolation of sterol-carrier proteins from liver that are believed to transport squalene as well as a wide range of sterols within the liver cell (3–5), the finding of increased plasma levels in the febrile phase of human Hong Kong influenza (6), the identification of squalene in human arterial atheromata (7), and the finding by Miettinen that levels of cholesterol precursors in plasma (C25–27 sterols and squalene) rise with increasing rates of whole body synthesis of cholesterol (8, 9). A recent report from this laboratory (10) has documented the very sizable secretion of squalene by the human skin along with other waxes, alcohols, and sterols: in five patients the daily secretion of squalene from the total skin surface ranged from 125–475 mg/day.

The present study was prompted largely by our efforts to devise a method for the measurement in man of total body synthesis of cholesterol in the unsteady state, a pressing need in certain studies of the mechanisms of action of hypocholesterolemic drugs and diets. On theoretical grounds it seemed reasonable to predict that the measurement of squalene synthesis rates would satisfy this need, in view of the rapidity of squalene synthesis and the small pool size of metabolically active squalene: the basic assumption was that squalene synthesis would equal cholesterol synthesis. Experiments along these lines are now in progress (11), but as support for the basic underlying premises it was clear from the onset that we needed considerably more detailed information about squalene metabolism in man than was available in the literature.

The present report describes the validation of a simplified method for measuring squalene concentrations in various body fluids and tissues. We also present (a) the results of applying this method to the measurement of squalene in a number of common foodstuffs; (b) plasma levels in relation to squalene intake and to plasma cholesterol and triglyceride concentrations; (c) concentrations in a wide variety of human tissues; (d) relationships between plasma squalene levels and rates of cholesterol synthesis; and (e) routes of excretion of squalene.

MATERIALS

Standards
Squalene and squalane were purchased from Eastman Kodak Company, Rochester, N. Y. Squalene (C30H48, mol

Abbreviations: GLC, gas-liquid chromatography

This is an Open Access article under the CC BY license.
Squalane (C29H48, mol wt 422.80; 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetraacosahexene) was found to be 97.5% pure by proton nuclear magnetic resonance, gas-liquid chromatography (GLC) and mass spectrometry; the major impurity was pristane, with trace amounts of squalane. Squalane was recovered by three extractions with 20 ml of petrol ether and subjected to alumina (neutral Alumina, AG 50, 200-mesh, Bio-Rad Laboratory, Richmond, Calif.) was heated overnight at 105°C, then reduced in activity by addition of 50 ml distilled water. Squalene (and squalane) were eluted with 50 ml of petrol ether. To recover cholesterol and other sterols it was necessary to elute subsequently with chloroform (100 ml); in tests with [3H]-squalene and [4C]cholesterol, there was no cross contamination of the hydrocarbon and sterol fractions.

After addition of a known amount of 5α-cholestanet (about 2 μg for plasma, 20–200 μg for bile and tissues) to the hydrocarbon fraction as a GLC recovery standard, the fraction was concentrated to near dryness by rotary evaporation and quantitatively transferred to a 15 ml stoppered vial; final drying of the specimen for application to a GLC column was carried out in a nitrogen stream. Six-foot columns (4 mm ID) of 1% Dexsil 300 on 100–200 mesh Supelcoport (Supelco, Inc., Bellefonte, Pa.) held at 235°C (flash heater 265°C, detector 255°C) had a resolving power of 2900 plates for squalene; nitrogen was used as carrier gas with an inlet pressure of 30 psi. Under these conditions the retention times relative to squalene (= 1.00) were: squalane 1.55, 5α-cholestanet 2.07, and cholesterol 4.92. A Packard gas chromatograph with hydrogen flame ionization detector, Model 7500, was used, coupled to a digital integrator for quantitation (Hewlett Packard Co., Palo Alto, Calif., Model 3370B).

Radioactivity measurements with external quench corrections were made on separate aliquots of the hydrocarbon fraction in a Packard Tri-Carb liquid scintillation spectrometer, Model 3390, with an absolute activity analyzer (Packard Model 544).

Calculations

The amount of squalene in the sample is calculated in terms of the relative areas of the squalene and squalane peaks in the final GLC analysis, where squalane was added at the outset as an overall recovery standard:

\[ \text{Squalene in sample (μg)} = \frac{\text{squalane area}}{\text{squalane area}} \times \frac{\text{μg squalane added}}{\text{μg squalane added}} \]

The recovery of squalane through the several purification steps is calculated in terms of the relative areas of squalane and of 5α-cholestanet added as a second recovery standard immediately prior to GLC analysis:

\[ \% \text{recovery of squalane} = \left[ \left( \frac{\text{squalane area}}{\text{5α-cholestanet area}} \times \frac{\text{μg 5α-cholestanet added}}{\text{μg squalane added}} \right) \times 100 \right] \]

Precautions

The high rate of secretion of squalene by the human skin

\[ \text{Liu et al. Squalene in human tissues} \]
leads to gross contamination of laboratory glassware unless exceptional care is taken to render every item squalene-free. Only after some experience is gained with the method is it feasible not to use polyvinyl gloves prerinsed with petrol ether. That squalene is an ideal recovery standard. The recoveries of radioactive squalene and of squalane were essentially the same. This suggests that squalene was not selectively lost or oxidized during the analysis; that the tritium label was not exchangeable during the procedure; and thus that squalene in biologic materials is resistant to oxidation under these conditions.

VALIDATION OF ANALYTICAL PROCEDURE

The usefulness of the procedure depends on the demonstration that the GLC responses of squalene, squalane, and 5α-cholestan e are linear in proportion to weight over a wide range. Evidence to support this conclusion is shown in Table 1, where recoveries of the three materials are related to each other over 20-fold concentration ranges. Each mixture of two compounds was analyzed in triplicate. It can be seen that coefficients of variation never exceeded 1% and that the percentage recoveries in the three sets of comparisons were very close to 100. Further evidence on reproducibility is given in Table 2, in which replicate analyses were carried out on biologic materials to which [3H]squalene as well as squalane were added as recovery standards. The coefficients of variation for plasma never exceeded 2%. It is seen that the recoveries of radioactive squalene and of squalane were essentially the same. This suggests that squalene was not selectively lost or oxidized during the analysis; that the tritium label was not exchangeable during the procedure; and thus that squalane is an ideal recovery standard. The recoveries of internal standards were only about 88% in analyses of feces and 82% for bile, as contrasted to 96% or more in plasma; nevertheless these were high enough, in our estima-

**TABLE 1. Linearity of GLC response to squalene using 5α-cholestan e and squalane as internal standards**

| Compound of Interest | Internal Standard | Recovery of Squalene Relative to 5α-cholestan e | Recoveries of Squalane and Squalane (Corrected for Recoveries) | Squalene Concentration (Corrected for Recoveries) |
|----------------------|------------------|-----------------------------------------------|---------------------------------------------------------------|-------------------------------------------------|
|                      |                  | **Recovery of Radiative** | **Relative** | **µg/dl** |
|                      |                  | **µg ± SD** | **%** | **µg/dl** |
|                      |                  | **µg ± SD** | **%** | **µg/dl** |
| Squalene recovery with 5α-cholestan e as standard | 1.91 | 3.99 | 1.87 ± 0.01 | 97.9 |
|                      | 3.82 | 3.99 | 3.80 ± 0.00 | 99.5 |
|                      | 5.73 | 3.99 | 5.74 ± 0.01 | 100.2 |
|                      | 7.64 | 3.99 | 7.86 ± 0.02 | 102.8 |
|                      | 11.46 | 3.99 | 11.46 ± 0.01 | 99.0 |
|                      | 19.10 | 3.99 | 19.17 ± 0.00 | 100.3 |
|                      | 38.20 | 3.99 | 38.42 ± 0.01 | 101.0 |

---

**TABLE 2. Reproducibility of squalene analysis in plasma, bile and feces (mean values ± SD)**

| Material Analyzed | Recovery of Radiative Internal Standard* | Recovery of Squalene Relative to 5α-cholestan e | Squalene Concentration (Corrected for Recoveries) |
|------------------|------------------------------------------|-----------------------------------------------|-------------------------------------------------|
| Plasma           | **%** | **%** | **µg/dl** |
| fresh pool*      | 16 | 97.8 ± 2.44 | 96.1 ± 2.09 | 26.2 ± 1.58 |
| stored pool†     | 4 | 97.1 ± 1.18 | 26.4 ± 1.81 |
| Bile*            | 4 | 81.8 ± 5.50 | 103.9 ± 10.9 |
| Feces*           | 4 | 88.2 ± 2.35 | 87.5 ± 2.30 | 4.75 ± 0.05 |

---

* [3H] squalene and/or squalane were added as overall recovery standards; 5α-cholestan e as GLC internal standard.
† This single pool consisted of plasma from freshly drawn bloods of ten donors; generously furnished by the N.Y. Blood Center.
‡ Same as (b) but analysis after storage at 4°C for 6 months.
§ Gallbladder bile samples obtained during exploratory laparotomy in four patients without hepatic-biliary disease.
* Stool collections under steady state conditions in four patients fed squalene-free diet (13).
so long as uncontaminated glassware is used throughout and samples are stored months' storage at 4°C. Knowledge, shark liver is not eaten by man, even in the USA population (Table 14). This finding suggests that retrospective analyses of squalene are reliable, so long as uncontaminated glassware is used throughout and samples are stored at 4°C.

APPLICATION OF THE METHOD

In the following section we will describe a few applications of the method in assessing certain parameters of squalene metabolism in man. The results to be presented are intended to be illustrative rather than comprehensive.

Squalene levels in foods

The primary source of commercial squalene is shark liver oil, in which concentrations of 50-60% are reached. (To our knowledge, shark liver is not eaten by man, even in the Orient.)

| Table 3. Squalene content in various foods (µg/g wet weight, mean of duplicate analyses) |
|-------------------------------|-------------------------------|
| **Food Fat**                  | **Meats**                     |
| Olive oil                     | Safflower oil                 | 37.2 |
| Cod liver oil                 | Cottonseed oil               | 27.8 |
| Corn oil                      | Lard                          | 22.5 |
| Sweet breads                  | Kidney                        | 18.7 |
| Beef                          | Liver                         | 18.5 |
| Chicken                       | Duck                          |      |
| Skin                          | Chicken                       | 14.0 |
| Dark meat                     | Dark meat                     | 20.5 |
| White meat                    | White meat                    | 36.4 |
| Turkey                        | Egg yolk                      | 47.0 |
| Fish                          | halibut                       | 30.0 |
| Flounder                      | Margarine                     | 16.9 |
| Cheese                        | whole homogenized             | 2.4 |
| Munster                       | skim                          | 1.5 |
| Avocado                       | Almond                        | 13.2 |
| artichoke (heart or leaf)     | Peaunt                        | 22.3 |
| Cashew                        | Pistachio                     | 15.1 |
| *Typical USA diet*            | 24-38 mg/2000 calories        |

a Samples of three brands were analyzed in duplicate.

b Homogenate of foodstuffs designated by a USDA survey (1965) to be representative of mean intake/person-year in the USA population (Table 6-1 in Ref. 14).

tion, to give confidence in any final results corrected by reference to the recoveries of appropriate internal standards.

The squalene contents of pooled plasmas, fresh and after 6 months' storage at 4°C, were almost identical. This finding suggests that retrospective analyses of squalene are reliable, so long as uncontaminated glassware is used throughout and samples are stored at 4°C.

Table 3 lists the concentrations of squalene in various foodstuffs that are prominent in the diets of the USA population. Of the food fats, olive oil is uniquely rich in squalene, but cod liver oil and corn oil contain significant quantities also. Poultry, red meats, and organ meats have about the same content, whereas halibut and flounder are somewhat richer in squalene.

A more useful benchmark is our finding that the average squalene intake of the USA population approaches 24 mg per 2000 calories per person per day. This figure is based on analyses of a homogenate of the foods most commonly eaten in this country, prepared with regard to the items and quantities of each that were identified in a survey published in 1965 by the U.S. Department of Agriculture (summarized recently in Table 6-1 of ref. 14).

Salad oils constituted 4.7% of total edible fat in this tabulation; in the homogenate we prepared, corn oil was selected as the salad oil. Had olive oil been taken instead of corn oil, the squalene content of this homogenate could have reached 38 mg/2000 calories.

Clearly, the daily squalene intake in this country must vary widely, depending on individual food preferences. However, a 2000-calorie diet rich in fish and salads dressed with olive oil could furnish as much as 200 mg squalene, suggesting this as a tentative maximum intake for man, except under highly artificial conditions (see below).

Plasma levels and their determinants

Table 2 shows that human plasma pooled from 10 healthy

| Patient, A. G. | Squalene-Free Diet* | High-Squalene Diet* |
|----------------|---------------------|---------------------|
| 53 yr male     | 64 ± 1.6            | 4555 ± 12.3         |
| 59 yr female   | 24 ± 1.3            | 129 ± 30.4         |
| hypercholesterolemia | (n = 3)     | (n = 4)            |
| hyperglyceridemia | 868 ± 19.8        | (n = 6)            |
| Patient, E. H. | 36 ± 16.8           | 79 ± 20.4          |
| 29 yr female   | (n = 6)             | (n = 5)            |
| hypercholesterolemia |            |                    |

* All diets were eucaloric in that body weight was maintained with less than 2% variation during steady state periods of 2-6 weeks' duration. The composition was liquid formula with squalene-free cottonseed oil comprising 45% of total daily calories.

b This formula diet contained olive oil as 45% of total calories. Squalene is endogenous in olive oil and the daily squalene intake was 692 and 375 mg per day in patients A.G. and R.B., respectively.

* These plasma squalene concentrations were reached after feeding the cottonseed oil formula with added squalene. Daily squalene intakes were 350 and 369 mg, respectively, in patients R.B. and E.H.

1 An analysis of this diet homogenate, in terms of major and minor nutrients, minerals, vitamins, etc., has been completed recently in this laboratory; a manuscript is in preparation.
instances one point represents the mean of more than patients single determinations were carried out, but in 18 ir-

There was no correlation between plasma squalene and choles-

terol concentrations were linearly correlated with an 

r value = 0.79, P < 0.01.

blood donors eating ad libitum (presumably their diets contained about 25 mg squalene per 2000 calories, Table 3) contained 26 μg squalene/dl plasma. Individual analyses of plasmas from 26 healthy fasting normolipidemic donors on ad libitum diets revealed: 33.7 ± 11.0 μg squalene/dl plasma (mean ± SD), with a range of 18.0 to 72.4 μg/dl. Table 4 shows that three patients fed much larger squalene intakes had substantially higher plasma squalene levels. In addition there was considerable person-to-person variation, the causes of which remain to be explored. However, it is noteworthy that Patient 1 had marked hyperglyceridemia at the time of this experiment, his plasma glycerides averaging 1000 mg/dl, total cholesterol 200 mg/dl; by contrast, Patients 2 and 3 had triglyceride levels of 85 and 60 mg/dl, respectively. Whether the high squalene levels achieved by Patient 1 simply reflect a solvation effect in the triglyceride core of his elevated very low-density lipoprotein fraction, or some other peculiarity of absorption and/or disposal of dietary squalene, remains to be explained.

Analyses of 138 plasma samples taken from 26 patients at various stages in medical management of various forms of hyperlipidemia showed (Fig. 1) that squalene levels were distinctly lower in hypercholesteremia (<35 μg/dl) than in hyperglyceridemia or mixed hyperlipidemia. There was a strong correlation between plasma triglyceride and squalene concentrations, though none with plasma cholesterol levels.

**Squalene levels in human tissues**

A wide variety of human tissues has been examined for their squalene and cholesterol concentrations. Table 5 presents the data; they are too few to warrant statistical analysis, but serve to give some tentative impressions of the relative amounts in different tissues. Since we could see no differences between analyses of tissues obtained at autopsy or at surgery, these data have been combined. Unfortunately, it was not practical to measure coincident plasma levels.

The data show a very wide variation in squalene concentration and in squalene/cholesterol ratios. Of all tissues, skin had the highest squalene level (on a dry weight basis), which is not surprising in view of the very sizable secretion of squalene by the sebaceous glands of the skin that can amount to 125-475 mg/day/person (10). Of the other organs and tissues, adipose tissue was the second richest in squalene, standing in a class by itself; since cholesterol synthesis in human adipocytes is exceedingly low (15), this finding suggests sequestration of squalene due to solvation. The third group, all with concentrations above 100 μg/g dry weight, consisted of lymph node, arterial intima, myocardium, skeletal muscle, and kidney. The contrast between arterial intima and media is striking for both squalene and cholesterol.

Among the remaining tissues that contained less than 100 μg/g, it is interesting to find liver and small intestine, the same organs in which cholesterol synthesis is considered to proceed most vigorously.

In the 27 tissues, the squalene/cholesterol ratio (μg/mg) ranged from essentially zero (erythrocytes) to nearly 100 (adipose tissues). In 19 of 27 tissues this ratio was 6.5 (liver) or less. In an intermediate group of three tissues the ratios varied from 14 to 19 (lymph node, pancreas, myocardiun), while three other tissues had strikingly higher ratios: skeletal muscle 42, skin 65, adipose tissue 90-97. The high ratio in adipose tissue lends to the idea that squalene may be sequestered with triglyceride by solvation. On the other hand, the tissues characterized by highest cholesterol synthesis capacities did not have high squalene/cholesterol ratios (liver 6.5, small intestine 3.9), except for skin.

**Plasma levels and cholesterol synthesis rates**

Miettinen (8, 9) showed that in man increased cholesterol synthesis rates were reflected by increased levels of C_{37-39},methyl sterols; in rats, plasma squalene levels also were increased. We attempted to extend his findings by analyzing the plasma levels of squalene in outpatients involved in a double-blind trial of cholestyramine vs. placebo (conducted by Dr. Richard Hoffman, Staten Island Hospital, Staten Island, New York, whose cooperation is gratefully acknowledged). We expected to find higher squalene levels during
TABLE 5. Squalene and cholesterol concentrations in 27 human tissues

| Bulk tissues       | Squalene Concentration | Cholesterol Concentration |
|--------------------|------------------------|---------------------------|
|                    | n | µg/g wet weight | µg/g dry weight* | mean | range | mean | range | mean | range | mean | range |
| Adipose tissue     | 3 | 164.0-473.3      | 389.9               | 266.2-555.1 | 1.6  | 1.5-1.7 | 1.8 | 1.5-2.0 | 96.7 |
| Subcutaneous fat   | 4 | 159.0-280.5      | 178.5               | 106.7-309.3 | 1.3  | 1.3     | 1.5 | 1.5     | 89.8 |
| Skin               | 4 | 148.4-328.8      | 478.1               | 208.0-1067.0| 1.1  | 1.0-1.3 | 3.5 | 3.1-4.0 | 64.5 |
| Arterial wall      | 5 | 29.9-53.3        | 32.0               | 10.1-199.8 | 9.1  | 2.6-29.3 | 7.8 | 5.6-38.5 | 4.7  |
| Intima             | 1 | 5.6             | 2.1-17.2           | 23.8       | 8.1-58.6 | 0.7 |
| Erythrocytes       | 2 | 0.2             | 0.1-0.4            | 1.2        |
| Endocrine organs   | Adrenal                | 4 | 22.1            | 16.1-31.8 | 64.9 | 48.7-95.8 | 84.3 | 33.3-114.5 | 234.8 | 100.0-350.7 | 0.4 |
| Testis             | 2 | 7.1             | 6.2-8.2            | 40.0       | 38.7-47.3 | 3.2  | 2.9-3.5 | 19.7 | 18.5-20.8 | 2.2  |
| Thyroid            | 4 | 4.7             | 3.4-7.6            | 20.8       | 14.4-31.1 | 1.8  | 1.2-2.3 | 7.8  | 6.0-10.7 | 2.7  |
| Ovary              | 2 | 1.4             | 0.8-1.9            | 8.1        | 4.5-11.6 | 2.3  | 1.5-3.0 | 13.5 | 8.1-18.8 | 0.6  |
| Other organs       | Lymph nodes            | 3 | 52.2            | 36.8-78.1 | 140.3 | 103.4-150.7 | 4.2  | 2.4-5.9 | 15.0 | 4.0-23.7 | 16.0 |
| Pancreas           | 4 | 29.9            | 6.8-68.4           | 97.0       | 21.0-190.6 | 2.4  | 2.2-2.8 | 9.2  | 6.2-10.7 | 14.3 |
| Myocardium         | 5 | 24.4            | 20.6-29.4          | 117.4      | 105.3-136.7 | 1.3  | 1.2-1.4 | 6.2  | 5.8-6.8 | 19.1 |
| Liver              | 5 | 21.8            | 17.4-27.9          | 75.1       | 56.3-92.3 | 3.6  | 2.8-5.6 | 12.4 | 9.9-18.8 | 6.5  |
| Large intestine    | 2 | 19.5            | 19.0-19.9          | 71.1       | 58.1-84.1 | 1.9  | 1.9     | 7.7  | 5.7-9.7 | 10.4 |
| Kidney             | 5 | 18.4            | 12.9-23.1          | 100.8      | 70.8-121.7 | 3.1  | 2.6-3.9 | 17.3 | 15.1-19.7 | 5.8  |
| Gall bladder       | 3 | 9.1             | 4.6-15.2           | 32.7       | 25.5-43.0 | 2.9  | 1.8-3.6 | 10.8 | 9.7-12.6 | 3.0  |
| Small intestine    | 2 | 8.2             | 8.0-8.3            | 42.2       | 41.1-43.4 | 2.1  | 2.0-2.2 | 11.0 | 10.6-11.4 | 3.9  |
| Cerebellum         | 3 | 7.3             | 4.7-12.0           | 43.7       | 28.3-72.6 | 12.9 | 8.0-18.3 | 69.0 | 50.8-80.9 | 0.4  |
| Prostate           | 6 | 6.8             | 31.0               | 31.0       | 12.8     | 2.3  | 12.8     | 2.6 |
| Cerebrum           | 3 | 5.6             | 3.1-8.0            | 22.7       | 14.5-30.9 | 19.3 | 18.3-20.0 | 85.8 | 75.1-96.4 | 0.2  |
| Lung               | 3 | 5.3             | 2.5-9.3            | 30.2       | 14.8-53.0 | 3.4  | 3.2-3.7 | 19.4 | 17.4-21.3 | 2.7  |
| Uterus             | 3 | 1.9             | 1.7-2.0            | 10.4       | 8.2-11.6 | 2.2  | 1.5-2.9 | 12.1 | 7.4-16.8 | 0.9  |
| Spleen             | 3 | 1.7             | 1.2-2.2            | 7.3        | 4.9-10.9 | 3.9  | 3.8-4.1 | 18.8 | 18.0-19.8 | 0.4  |

*Dried at 60°C for 3 days or until no further weight was lost.

mg/ml packed cells; from Parquhar, J. W. 1962. Human Erythrocyte Phospholipids. Biochem. Biophys. Acta. 60: 80-89.

Cholesteryamine treatment, since this drug is known to cause a marked increase in cholesterol synthesis (16), and indeed 18 patients given the drug had a mean plasma squalene level of 84 µg/dl (SD ± 110), while 9 other patients on placebo medication had a mean level of 56 ± 28 µg/dl. It is obvious that the range of variation in both groups was very large, due perhaps to the uncontrolled (and presumably different) levels of squalene intake among these outpatients.

However, under conditions where dietary intakes of squalene are negligible (as can be achieved with formula feeding regimens), it is possible that plasma squalene levels may vary directly with cholesterol synthesis rates. Some support for this has been shown in Fig. 1: since synthesis rates have been shown to be higher in some patients with hyperglyceridemia than in those with hypercholesteremia (17-19), it is relevant to find that there was a direct correlation between squalene and triglyceride levels in these patients fed squalene-free formulas. Low squalene concentrations were seen consistently in hypercholesteremic patients and in successfully treated hyperglyceridemic patients.

Hypocaloric diets and fasting are thought to cause a reduction in cholesterol synthesis (20). Six patients studied during weight maintenance and then during weight reduction on hypocaloric diets (squalene-free) showed a fall in mean plasma squalene levels from 32.9 ± 5.8 µg/dl (n = 11) to 24.1 ± 8.5 µg/dl (n = 12) (P < 0.005). These changes were independent of plasma triglyceride changes: significant increases in glyceride levels occurred in two patients, decreases in two, and insignificant changes in two.

Excretion of squalene

Reference has been made to previous work in this laboratory that defined the large excretion of squalene by the human skin (10). In a subsequent related report (21) it was shown that a major proportion of the cholesterol secreted by the skin is made there de novo, in contrast to being transferred through the skin from plasma. Thus, it seems likely that the skin secretion of squalene also reflects de novo synthesis rather than transfer from the plasma.

Liu et al. Squalene in human tissues 43
The data in Table 2 showed that squalene levels in bile were much higher than in plasma, and random samples of feces of patients on squalene-free diets also contained squalene. In order to estimate total excretion of squalene in feces, and as a background for future studies of squalene absorption, we measured the daily excretion rates of fecal squalene in three patients at constant body weight under controlled conditions on squalene-free, normal-cholesterol diets (two stool collections each). On weighed low-squalene solid foods, S.H. excreted 1.46 and 1.70 mg squalene per day; A.J. 2.95 and 2.83 mg/day; B.E., who was maintained solely on a squalene-free diet, excreted 0.66 and 0.44 mg/day. Whether squalene is degraded in its passage through the intestinal tract of man cannot yet be stated with certainty, but in vitro incubations of fresh human feces with labeled and unlabeled squalene/squalane mixtures have shown no changes in the ratio of squalene to its indicator.

We have analyzed pooled urine samples from four patients for squalene radioactivity at appropriate intervals after the intravenous administration of 230 μCi [2-14C] mevalonate. Although plasma specific activity usually rose over 250 dpm/mg, there were no detectable counts found in any of the urinary nonsaponifiable fractions.

DISCUSSION

The method described for measurement of squalene mass (and specific activity, where appropriate labeling has occurred) appears to be accurate and reproducible, provided certain precautions are taken to avoid contamination by squalene secreted from skin. We believe it represents a significant improvement in precision over previous nonspecific methods based on isolation and iodimetry (22); it is somewhat simpler than the methods used by Brooks (7) and Goodman (1); the isolation procedure resembles that of Eidinoff et al. (23). Recoveries of squalene from biologic samples exceeded 82% in all cases, and with the use of internal standards the appropriate corrections could be made easily and accurately.

A number of applications of the method have been described, but much more remains to be undertaken if we are to gain a better understanding of the metabolism in man of this key intermediate in biosynthesis of cholesterol. The data in Table 5 demonstrate the widespread occurrence of squalene in almost all body tissues; a minimum estimate of total body squalene (based on the concentrations found in discrete organs and bulk tissues but exclusive of nervous and vascular systems) could reach 2.6 g. Yet, our studies of squalene kinetics (11) indicate that the size of the pool of metabolically active squalene in man (i.e., that which is rapidly converted to cholesterol) is only about 300 mg. This finding that the equilibration between the active and inactive pools of squalene must be extremely sluggish simply confirms the earlier studies of squalene compartments in rat liver by Pojásk (24) and by Loud and Bucher (25) which indicated that the active squalene pool was very small in comparison with the inactive pool. Why this disequilibrium exists remains to be explained. The transfer of squalene across cer-

ADDENDUM

Two additional references to squalene contents of foods have been noted since this paper was completed. Fresh tuna meat was reported to contain 0.014 mg squalene per g wet weight, mackerel and bonito 0.011, mullet 0.002 (R. W. Lewis. 1971. Squalene distribution in fish with normal and pathologically fatty livers. Int. J. Biochem. 2: 609–614); avocado pear (skinned) 0.044 mg/g wet weight; eggplant 0.0024; carrots, apple, squash, banana, peas, mushroom 0.0012 or less (R. W. Lewis. 1972. Squalene content of plant tissues. Phytochemistry. 11: 417–419).

There is no consensus whether human atheromata contain an elevated content of squalene. Brooks et al. (7) reported 1000 μg/g wet weight in aortic plaques, whereas a recent report by Lewis (R. W. Lewis. 1975. Squalene content of atheromatous plaques. Atherosclerosis. 22: 637–640) noted no values higher than 1.3 μg/g in plaques, compared to 0.46 in normal aortas. In our study (Table 5) we report 40 μg squalene per g wet weight of normal aortic intimas, a 100-fold higher concentration than that recorded by Lewis, but only one-twenty fifth that reported by Brooks et al. (7).

The authors gratefully acknowledge the excellent technical assistance of Mrs. Christina Parsons, Mrs. Linda Mack-soud, Mrs. Jessica Percival and Mrs. Eleanor Mathusek.

This study was supported in part by U. S. Public Health Service grant HL-06222 from the National Heart and Lung Institute, and by U. S. Public Health Service grant FR-00102 from the General Clinical Research Centers Branch of the Division of Research Resources, and by the New York Heart Association. Dr. John R. Crouse is the recipient of a New York Heart Association Fellowship.

Manuscript received 18 May 1975; accepted 8 September 1975.
REFERENCES

1. Goodman, DeW. S. 1964. Squalene in human and rat blood plasma. *J. Clin. Invest.* 43: 1480-1485.
2. Langdon, R. G. and K. Bloch. 1953. The utilisation of squalene in the biosynthesis of cholesterol. *J. Biol. Chem.* 200: 135-143.
3. Seallen, T. J., M. W. Schuster, and A. K. Dhar. 1971. Evidence for a noncatalytic carrier protein in cholesterol biosynthesis. *J. Biol. Chem.* 246: 224-230.
4. Ritter, M. C., and M. F. Dempsey. 1971. Specificity and role in cholesterol biosynthesis of a squalene and sterol carrier protein. *J. Biol. Chem.* 246: 1536-1539.
5. Rilling, H. C. 1972. The effect of sterol carrier protein on squalene synthesis. *Biochem. Biophys. Res. Commun.* 46: 470-475.
6. Gallin, J. I., W. M. O'Leary, and D. Kaye. 1970. Increased serum levels of squalene in patients with acute influenza. *N. Engl. J. Med.* 282: 1225-1227.
7. Brooks, C. J. W., G. Steel, and W. A. Haslaid. 1970. Lipids of human atheroma VI. Hydrocarbons of the atheromatous plaque. *Lipids.* 5: 818-824.
8. Miettinen, T. A. 1969. Serum squalene and methylsterols as indicators of cholesterol synthesis in vivo. *Life Sci.* 8: 713-721.
9. Miettinen, T. A. 1970. Detection of changes in human cholesterol metabolism. *Ann. Clin. Res.* 2: 300-320.
10. Nikkari, R., P. H. Schreibman, and E. H. Ahrens, Jr. 1974. In vivo studies of sterol and squalene secretion by human skin. *J. Lipid Res.* 15: 563-573.
11. Liu, G. C. K., E. H. Ahrens, Jr., P. H. Schreibman, P. Samuel, D. J. McNamara, and J. R. Crouse. 1975. Measurement of cholesterol synthesis in man by isotope kinetics of squalene. *Proc. Nat. Acad. Sci.* 72: 4612-4616.
12. Popjak, G., and J. W. Cornforth. 1966. Substrate stereochemistry in squalene biosynthesis. *Biochem. J.* 101: 553-568.
13. Ahrens, E. H., Jr. 1970. The use of liquid formula diets in metabolic studies: 15 years' experience. In Advances in Metabolic Disorders, Vol. 4, R. Levine and R. Luft, editors, Academic Press, New York, pp. 297-332.
14. Mass Field Trials of the Diet-Heart Question. Their significance, timeliness, feasibility and applicability. An assessment of seven proposed experimental designs. Report of the diet-heart review panel of the National Heart Institute, June 1969. E. H. Ahrens, Jr., panel chairman. American Heart Association, Inc., Monograph Number 28, 1969.
15. Schreibman, P. H., and R. B. Dell. 1975. Human adipocyte cholesterol: concentration, localisation, synthesis and turnover. *J. Clin. Invest.* 55: 986-993.
16. Grundy, S. M., E. H. Ahrens, Jr., and G. Salen. 1971. Interruption of enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. *J. Lab. Clin. Med.* 78: 94-121.
17. Miettinen, T. A. 1971. Cholesterol metabolism in patients with coronary heart disease. *Ann. Clin. Res.* 3: 313-322.
18. Solth, H. S., and B. Kudachodkar. 1973. Correlating metabolism of plasma and tissue cholesterol with that of plasma-lipoproteins. *Lancet* 1: 513-519.
19. Grundy, S. M. 1975. Effects of polyunsaturated fats on lipid metabolism in patients with hypertriglyceridemia. *J. Clin. Invest.* 55: 269-282.
20. Miettinen, T. A. 1971. Cholesterol production in obesity. *Circulation.* 44: 842-850.
21. Nikkari, T., P. H. Schreibman and E. H. Ahrens, Jr. 1975. Isotopic kinetics of human skin cholesterol secretion. *J. Exp. Med.* 141: 620-633.
22. Fitelson, J. 1943. Detection of olive oil in edible oil mixtures. *J. Assoc. Off. Agric. Chem.* 26: 499-506.
23. Eidinoff, M. L., R. S. Rosenfeld, J. E. Knoll, B. J. Marano, and L. Hellman. 1954. The biosynthesis of squalene from acetate in man. *J. Clin. Invest.* 33: 333-336.
24. Popjak, G. 1954. Biosynthesis of squalene and cholesterol in vitro from acetate 1-14C. *Arch. Biochem. Biophys.* 48: 102-106.
25. Loud, A. V., and N. L. R. Bucher. 1958. The turnover of squalene in relation to the biosynthesis of cholesterol. *J. Biol. Chem.* 233: 37-41.
26. Channon, H. J., and G. R. Tristram. 1937. XCVIII. The effect of the administration of squalene and other hydrocarbons on cholesterol metabolism in the rat. *Biochem. J.* 31: 730-747.
27. Dietschy, J. M., and J. D. Wilson. 1970. Regulation of cholesterol metabolism. *N. Engl. J. Med.* 282: 1128-1138, 1179-1183, 1241-1249.
28. Quintão, E., S. M. Grundy, and E. H. Ahrens, Jr. 1971. Effects of dietary cholesterol on the regulation of total body cholesterol in man. *J. Lipid Res.* 12: 233-247.